🍽️ ifenprodil tartrate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Neuroprotective Effects: Ifenprodil tartrate has been studied for its potential neuroprotective effects, particularly in conditions involving excitotoxicity and neuronal damage, such as stroke and neurodegenerative diseases like Alzheimer's disease and Parkinson's disease. By blocking NMDA receptors, ifenprodil tartrate may help prevent excessive glutamate-induced neuronal injury.

  2. Cognitive Effects: Some studies suggest that ifenprodil tartrate may have cognitive-enhancing effects, possibly by modulating neurotransmitter systems involved in learning and memory processes. However, more research is needed to fully understand its impact on cognitive function.

  3. Psychiatric Disorders: Ifenprodil tartrate's modulation of glutamatergic neurotransmission may have implications for psychiatric disorders such as depression, anxiety, and schizophrenia, which are thought to involve dysfunction of glutamatergic signaling pathways. However, its efficacy and safety in these conditions remain to be fully elucidated.

  4. Cardiovascular Effects: Ifenprodil tartrate may have some cardiovascular effects, as it has been shown to inhibit certain types of ion channels in the heart. However, the clinical significance of these effects is not well-understood.

  5. Side Effects: Like any medication, ifenprodil tartrate may cause side effects. Common side effects reported in preclinical studies include dizziness, sedation, gastrointestinal disturbances, and changes in blood pressure and heart rate. However, the full spectrum of side effects and their prevalence in humans is not well-established.

  6. Drug Interactions: Ifenprodil tartrate may interact with other medications or substances, particularly those that affect glutamatergic neurotransmission or cardiovascular function. Patients should consult their healthcare providers before taking ifenprodil tartrate concomitantly with other medications.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of ifenprodil tartrate,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by ifenprodil tartrate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Odoribacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of ifenprodil tartrate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
ADHD 0.5 0.5
Age-Related Macular Degeneration and Glaucoma 0.4 0.1 3
Allergic Rhinitis (Hay Fever) 0.1 0.1
Allergies 0.4 -0.4
Allergy to milk products 0.1 -0.1
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 0.2 1.4 -6
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.1 0 0
Ankylosing spondylitis 0.5 0.5
Anorexia Nervosa 0.1 0.4 -3
Antiphospholipid syndrome (APS) 0.1 -0.1
Asthma 0.4 -0.4
Atherosclerosis 0.5 -0.5
Atrial fibrillation 0.1 0.5 -4
Autism 0.9 1 -0.11
Bipolar Disorder 0.2 0.4 -1
Brain Trauma 0.4 -0.4
Cancer (General) 0 0
Carcinoma 0.2 0.1 1
Celiac Disease 0 0.2 0
Cerebral Palsy 0 0.4 0
Chronic Fatigue Syndrome 0.1 0.4 -3
Chronic Kidney Disease 0.1 0.4 -3
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.4 -0.4
Chronic Urticaria (Hives) 0.4 -0.4
Coagulation / Micro clot triggering bacteria 0.1 0.4 -3
Colorectal Cancer 0.5 0.5
Constipation 0.4 -0.4
COVID-19 0.1 0.8 -7
Crohn's Disease 0.6 0.5 0.2
cystic fibrosis 0.4 -0.4
deep vein thrombosis 0.4 -0.4
Depression 1 0.5 1
Endometriosis 0.1 0 0
Epilepsy 0 0.1 0
Fibromyalgia 0.5 0.3 0.67
Functional constipation / chronic idiopathic constipation 0.1 0.8 -7
gallstone disease (gsd) 0.1 0.4 -3
Graves' disease 0.1 0.4 -3
Hashimoto's thyroiditis 0.4 0.1 3
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues 0.4 0.4
hypercholesterolemia (High Cholesterol) 0 0 0
hyperglycemia 0.1 -0.1
Hyperlipidemia (High Blood Fats) 0 0
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 0.1 1.4 -13
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.3 -0.3
Inflammatory Bowel Disease 1 -1
Insomnia 0.4 -0.4
Intelligence 0.3 -0.3
Intracranial aneurysms 0.1 0.1
Irritable Bowel Syndrome 0.4 0.5 -0.25
Liver Cirrhosis 0.6 0.5 0.2
Long COVID 0.1 0.6 -5
Low bone mineral density 0.4 -0.4
Lung Cancer 0 0
ME/CFS without IBS 0.1 0.2 -1
Metabolic Syndrome 0.6 1.5 -1.5
Mood Disorders 1.2 0.5 1.4
multiple chemical sensitivity [MCS] 0 0
Multiple Sclerosis 0.2 1 -4
Multiple system atrophy (MSA) 0.9 0.9
neuropathic pain 0.8 -0.8
Neuropathy (all types) 0 0
neuropsychiatric disorders (PANDAS, PANS) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.3 0 0
Obesity 1.5 0.1 14
obsessive-compulsive disorder 0.1 0.4 -3
Osteoporosis 0 0
pancreatic cancer 0 0
Parkinson's Disease 0.2 0.4 -1
Polycystic ovary syndrome 0.1 0.5 -4
Premenstrual dysphoric disorder 0.1 -0.1
Psoriasis 0 1 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.9 0.4 1.25
Rosacea 0.4 -0.4
Schizophrenia 0.2 0.4 -1
scoliosis 0.1 -0.1
Sjögren syndrome 0.4 0.1 3
Sleep Apnea 0.4 -0.4
Stress / posttraumatic stress disorder 0.5 0.4 0.25
Systemic Lupus Erythematosus 0.2 0.4 -1
Tic Disorder 0 0.3 0
Tourette syndrome 0 0
Type 1 Diabetes 0.1 0.4 -3
Type 2 Diabetes 0.6 0.5 0.2
Ulcerative colitis 1 -1
Unhealthy Ageing 0.1 0.5 -4

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]